Cell line for the production of prostacyclin and uses thereof

Abstract

Provided herein are methods for producing a biomolecule by converting or engineering a plurality of cells, e.g., mammalian cells, having an endogenous precursor of a biomolecule to cells transfected to contain a nucleic acid that stably overexpresses a hybrid enzyme effective to metabolized the precursor to the biomolecule in the cell, e.g., prostacyclin produced from arachidonic acid. Also provided are methods of treating a pathophysiological condition associated with at least a decrease in the biomolecule or treating a vascular disease by administering the engineered, stably transfected mammalian cells to a subject where production of the biomolecule treats the condition or vascular disease. Further provided are the recombinant hybrid enzymes and the engineered cell lines and pharmaceutical compositions thereof, the nucleic acids encoding the hybrid enzymes, and vectors comprising the nucleic acids.

Dependencies are inferred from the claim text.